MiR-31 modulates dystrophin expression: New implications for Duchenne muscular dystrophy therapy

EMBO Reports

Volumn 12, Issue 2, 2011, Pages 136-141

  Cacchiarelli, Davide ^a   Incitti, Tania ^a   Martone, Julie ^a   Cesana, Marcella ^a   Cazzella, Valentina ^a   Santini, Tiziana ^a   Sthandier, Olga ^a   Bozzoni, Irene ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

DMD; dystrophin; gene therapy; miRNA; myoblasts

Indexed keywords

DYSTROPHIN; MICRORNA; MICRORNA 31; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ARTICLE; CELL MATURATION; CONTROLLED STUDY; DUCHENNE MUSCULAR DYSTROPHY; EXON; GENE ACTIVITY; GENE IDENTIFICATION; GENE REPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; MUSCLE CELL; MYOBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS;

3' UNTRANSLATED REGIONS; ANIMALS; CELL DIFFERENTIATION; CELLS, CULTURED; DYSTROPHIN; GENE EXPRESSION PROFILING; HUMANS; MICE; MICE, INBRED MDX; MICRORNAS; MUSCULAR DYSTROPHY, DUCHENNE; MYOTONIA CONGENITA; RNA INTERFERENCE; RNA, MESSENGER; SATELLITE CELLS, SKELETAL MUSCLE;

EID: 79551594779     PISSN: 1469221X     EISSN: 14693178     Source Type: Journal    
DOI: 10.1038/embor.2010.208     Document Type: Article

References (24)

1. Aartsma-Rus A, Janson AA, Kaman WE, Bremmer-Bout M, den Dunnen JT, Baas F, van Ommen GJ, van Deutekom JC (2003) Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients. Hum Mol Genet 12: 907-914
2. Alter J, Lou F, Rabinowitz A, Yin H, Rosenfeld J, Wilton SD, Partridge TA, Lu QL (2006) Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat Med 12: 175-177
3. Bremmer-Bout M, Aartsma-Rus A, De Meijer EJ, Kaman WE, Janson AA, Vossen RH, van Ommen GJ, den Dunnen JT, van Deutekom JC (2004) Targeted exon skipping in transgenic hDMD mice: a model for direct preclinical screening of human-specific antisense oligonucleotides. Mol Ther 10: 232-240
4. Cacchiarelli D et al (2010) microRNAs involved in molecular circuitries relevant for the Duchenne muscular dystrophy pathogenesis are controlled by the dystrophin/nNOS pathway. Cell Metab 12: 341-351
5. Chen JF, Mandel EM, Thomson JM, Wu Q, Callis TE, Hammond SM, Conlon FL, Wang DZ (2006) The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat Genet 38: 228-233
6. Daubas P, Crist CG, Bajard L, Relaix F, Pecnard E, Rocancourt D, Buckingham M (2009) The regulatory mechanisms that underlie inappropriate transcription of the myogenic determination gene Myf5 in the central nervous system. Dev Biol 327: 71-82
7. De Angelis FG, Sthandier O, Berarducci B, Toso S, Galluzzi G, Ricci E, Cossu G, Bozzoni I (2002) Chimeric snRNA molecules carrying antisense sequences against the splice junctions of exon 51 of the dystrophin pre-mRNA induce exon skipping and restoration of a corrected phenotype in D48-50, DMD cells. Proc Natl Acad Sci USA 99: 9456-9461
8. Denti MA, Rosa A, Sthandier O, De Angelis FG, Bozzoni I (2004) A novel vector for siRNA expression in mammalian cells that relies on polII-dependent transcription. Mol Ther 10: 191-199
9. Denti MA et al (2006) Body-wide gene therapy of Duchenne muscular dystrophy in the mdx mouse model. Proc Natl Acad Sci USA 103: 3758-3763
10. Denti MA, Incitti T, Sthandier O, Nicoletti C, De Angelis FG, Rizzuto E, Auricchio A, Musarò A, Bozzoni I (2008) Long-term benefit of adeno-associated virus/antisense-mediated exon skipping in dystrophic mice. Hum Gene Ther 19: 601-608
11. Dunckley MG, Manoharan M, Villiet P, Eperon IC, Dickson G (1998) Modification of splicing in the dystrophin gene in cultured Mdx muscle cells by antisense oligoribonucleotides. Hum Mol Genet 7: 1083-1090
12. Eisenberg I et al (2007) Distinctive patterns of microRNA expression in primary muscular disorders. Proc Natl Acad Sci USA 104: 17016-17021
13. Fletcher S, Honeyman K, Fall AM, Harding PL, Johnsen RD, Wilton SD (2006) Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligonucleotide. J Gene Med 8: 207-216
14. Gentner B, Schira G, Giustacchini A, Amendola M, Brown BD, Ponzoni M, Naldini L (2009) Stable knockdown of microRNA in vivo by lentiviral vectors. Nat Methods 6: 63-66
15. Goyenvalle A, Vulin A, Fougerousse F, Leturcq F, Kaplan JC, Garcia L, Danos O (2004) Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping. Science 306: 1796-1799
16. Greco S et al (2009) Common micro-RNA signature in skeletal muscle damage and regeneration induced by Duchenne muscular dystrophy and acute ischemia. FASEB J 23: 3335-3346
17. Incitti T, De Angelis FG, Cazzella V, Sthandier O, Pinnarò C, Legnini I, Bozzoni I (2010) Exon skipping and Duchenne muscular dystrophy therapy: selection of the most active U1 snRNA-antisense able to induce dystrophin exon 51 skipping. Mol Ther 18: 1675-1682
18. Naguibneva I, Ameyar-Zazoua M, Polesskaya A, Ait-Si-Ali S, Groisman R, Souidi M, Cuvellier S, Harel-Bellan A (2006) The microRNA miR-181 targets the homeobox protein Hox-A11 during mammalian myoblast differentiation. Nat Cell Biol 8: 278-284
19. Pena JT et al (2009) miRNA in situ hybridization in formaldehyde and EDC-fixed tissues. Nat Methods 6: 139-141
20. Rando TA, Blau HM (1994) Primary mouse myoblast purification, characterization, and transplantation for cell-mediated gene therapy. J Cell Biol 125: 1275-1287
21. Taulli R, Bersani F, Foglizzo V, Linari A, Vigna E, Ladanyi M, Tuschl T, Ponzetto C (2009) The muscle-specific microRNA miR-206 blocks human rhabdomyosarcoma growth in xenotransplanted mice by promoting myogenic differentiation. J Clin Invest 119: 2366-2378
22. Valastyan S, Weinberg RA (2010) miR-31: a crucial overseer of tumor metastasis and other emerging roles. Cell Cycle 9: 2124-2129
23. Van Deutekom JC et al (2007) Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med 357: 2677-2686
24. Van Rooij E, Marshall WS, Olson EN (2008) Toward microRNA-based therapeutics for heart disease: the sense in antisense. Circ Res 103: 919-928